Cargando…

Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity

Cardiotrophin-1 (CT-1) is a heart-targeting cytokine that has been reported to exert a variety of activities also in other organs such as the liver, adipose tissue, and atherosclerotic arteries. CT-1 has been shown to induce these effects via binding to a transmembrane receptor, comprising the leuka...

Descripción completa

Detalles Bibliográficos
Autores principales: Asrih, Mohamed, Mach, François, Quercioli, Alessandra, Dallegri, Franco, Montecucco, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649684/
https://www.ncbi.nlm.nih.gov/pubmed/23690661
http://dx.doi.org/10.1155/2013/370715
_version_ 1782269016915574784
author Asrih, Mohamed
Mach, François
Quercioli, Alessandra
Dallegri, Franco
Montecucco, Fabrizio
author_facet Asrih, Mohamed
Mach, François
Quercioli, Alessandra
Dallegri, Franco
Montecucco, Fabrizio
author_sort Asrih, Mohamed
collection PubMed
description Cardiotrophin-1 (CT-1) is a heart-targeting cytokine that has been reported to exert a variety of activities also in other organs such as the liver, adipose tissue, and atherosclerotic arteries. CT-1 has been shown to induce these effects via binding to a transmembrane receptor, comprising the leukaemia inhibitory factor receptor (LIFRβ) subunit and the glycoprotein 130 (gp130, a common signal transducer). Both local and systemic concentrations of CT-1 have been shown to potentially play a critical role in obesity. For instance, CT-1 plasma concentrations have been shown to be increased in metabolic syndrome (a cluster disease including obesity) probably due to adipose tissue overexpression. Interestingly, treatment with exogenous CT-1 has been shown to improve lipid and glucose metabolism in animal models of obesity. These benefits might suggest a potential therapeutic role for CT-1. However, beyond its beneficial properties, CT-1 has been also shown to induce some adverse effects, such as cardiac hypertrophy and adipose tissue inflammation. Although scientific evidence is still needed, CT-1 might be considered as a potential example of damage/danger-associated molecular pattern (DAMP) in obesity-related cardiovascular diseases. In this narrative review, we aimed at discussing and updating evidence from basic research on the pathophysiological and potential therapeutic roles of CT-1 in obesity.
format Online
Article
Text
id pubmed-3649684
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36496842013-05-20 Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity Asrih, Mohamed Mach, François Quercioli, Alessandra Dallegri, Franco Montecucco, Fabrizio Mediators Inflamm Review Article Cardiotrophin-1 (CT-1) is a heart-targeting cytokine that has been reported to exert a variety of activities also in other organs such as the liver, adipose tissue, and atherosclerotic arteries. CT-1 has been shown to induce these effects via binding to a transmembrane receptor, comprising the leukaemia inhibitory factor receptor (LIFRβ) subunit and the glycoprotein 130 (gp130, a common signal transducer). Both local and systemic concentrations of CT-1 have been shown to potentially play a critical role in obesity. For instance, CT-1 plasma concentrations have been shown to be increased in metabolic syndrome (a cluster disease including obesity) probably due to adipose tissue overexpression. Interestingly, treatment with exogenous CT-1 has been shown to improve lipid and glucose metabolism in animal models of obesity. These benefits might suggest a potential therapeutic role for CT-1. However, beyond its beneficial properties, CT-1 has been also shown to induce some adverse effects, such as cardiac hypertrophy and adipose tissue inflammation. Although scientific evidence is still needed, CT-1 might be considered as a potential example of damage/danger-associated molecular pattern (DAMP) in obesity-related cardiovascular diseases. In this narrative review, we aimed at discussing and updating evidence from basic research on the pathophysiological and potential therapeutic roles of CT-1 in obesity. Hindawi Publishing Corporation 2013 2013-04-10 /pmc/articles/PMC3649684/ /pubmed/23690661 http://dx.doi.org/10.1155/2013/370715 Text en Copyright © 2013 Mohamed Asrih et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Asrih, Mohamed
Mach, François
Quercioli, Alessandra
Dallegri, Franco
Montecucco, Fabrizio
Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity
title Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity
title_full Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity
title_fullStr Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity
title_full_unstemmed Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity
title_short Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity
title_sort update on the pathophysiological activities of the cardiac molecule cardiotrophin-1 in obesity
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649684/
https://www.ncbi.nlm.nih.gov/pubmed/23690661
http://dx.doi.org/10.1155/2013/370715
work_keys_str_mv AT asrihmohamed updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity
AT machfrancois updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity
AT querciolialessandra updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity
AT dallegrifranco updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity
AT montecuccofabrizio updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity